All Stories

  1. ARID1A in Gynecologic Precancers and Cancers

    Article • Reproductive Sciences, May 2024, Springer Science + Business Media

    Gloria Huang

  2. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

    Article • British Journal of Cancer, March 2024, Springer Science + Business Media

    Gloria Huang

  3. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

    Article • Annals of Surgical Oncology, June 2023, Springer Science + Business Media

    Gloria Huang

  4. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

    Article • Gynecologic Oncology, May 2023, Elsevier

    Gloria Huang

  5. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”

    Article • Gynecologic Oncology, March 2023, Elsevier

    Gloria Huang

  6. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo

    Article • Gynecologic Oncology, March 2023, Elsevier

    Gloria Huang

  7. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

    Article • Gynecologic Oncology, March 2023, Elsevier

    Gloria Huang

  8. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor

    Article • Gynecologic Oncology, February 2023, Elsevier

    Gloria Huang

  9. What role does adjuvant therapy play in the management of endometrial cancer?

    Article • Expert Opinion on Pharmacotherapy, January 2023, Taylor & Francis

    Gloria Huang

  10. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

    Article • Gynecologic Oncology, January 2023, Elsevier

    Gloria Huang

  11. Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer

    Article • Frontiers in Oncology, August 2022, Frontiers

    Gloria Huang

  12. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu

    Article • Gynecologic Oncology, August 2022, Elsevier

    Gloria Huang

  13. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

    Article • Gynecologic Oncology, July 2022, Elsevier

    Gloria Huang

  14. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

    Article • British Journal of Cancer, February 2022, Springer Science + Business Media

    Gloria Huang

  15. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

    Article • Cancer, December 2021, Wiley

    Gloria Huang

  16. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy

    Article • Gynecologic Oncology, December 2021, Elsevier

    Gloria Huang

  17. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

    Article • Gynecologic Oncology, November 2021, Elsevier

    Gloria Huang

  18. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu

    Article • Gynecologic Oncology, October 2021, Elsevier

    Gloria Huang

  19. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

    Article • Annals of Oncology, August 2021, Elsevier

    Gloria Huang

  20. Integrated mutational landscape analysis of uterine leiomyosarcomas

    Article • Proceedings of the National Academy of Sciences, April 2021, Proceedings of the National Academy of Sciences

    Gloria Huang

  21. Sex Hormone, Insulin and Insulin-like Growth Factor in Recurrence of High Stage Endometrial Cancer

    Article • Cancer Epidemiology Biomarkers & Prevention, February 2021, American Association for Cancer Research (AACR)

    Professor David Scott Miller, Gloria Huang

  22. Financial toxicity in patients with gynecologic malignancies: a cross sectional study

    Article • Journal of Gynecologic Oncology, January 2021, XMLink

    Gloria Huang

  23. Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence

    Article • Frontiers in Artificial Intelligence, November 2020, Frontiers

    Gloria Huang

  24. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study

    Article • Gynecologic Oncology Reports, November 2020, Elsevier

    Gloria Huang

  25. Vulnerability of ARID1A deficient cancer cells to pyrimidine synthesis blockade

    Article • October 2020, Cold Spring Harbor Laboratory Press

    Gloria Huang

  26. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

    Article • Gynecologic Oncology, September 2020, Elsevier

    Gloria Huang

  27. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma

    Article • Gynecologic Oncology, February 2020, Elsevier

    Gloria Huang

  28. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

    Article • Scientific Reports, January 2020, Springer Science + Business Media

    Gloria Huang

  29. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

    Article • Molecular Oncology, January 2020, Wiley

    Gloria Huang

  30. Stage III uterine serous carcinoma: modern trends in multimodality treatment

    Article • Journal of Gynecologic Oncology, January 2020, Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy (KAMJE)

    Gloria Huang

  31. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

    Article • Proceedings of the National Academy of Sciences, October 2019, Proceedings of the National Academy of Sciences

    Gloria Huang

  32. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib

    Article • Gynecologic Oncology, October 2019, Elsevier

    Gloria Huang

  33. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A

    Article • Cancer Research, August 2019, American Association for Cancer Research (AACR)

    Gloria Huang

  34. Neutrophil count predicts mortality in women with aggressive uterine cancer.

    Article • International Journal of Gynecological Cancer, July 2019, BMJ

    Gloria Huang

  35. Stratifying Ovarian Cancer Risk Using Personal Health Data

    Article • Frontiers in Big Data, July 2019, Frontiers

    Gloria Huang

  36. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers

    Article • Gynecologic Oncology, April 2019, Elsevier

    Gloria Huang

  37. Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

    Article • Proceedings of the National Academy of Sciences, March 2019, Proceedings of the National Academy of Sciences

    Gloria Huang

  38. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

    Article • Proceedings of the National Academy of Sciences, December 2018, Proceedings of the National Academy of Sciences

    Gloria Huang

  39. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

    Article • Clinical Cancer Research, October 2018, American Association for Cancer Research (AACR)

    Gloria Huang

  40. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

    Article • Journal of Cancer Research and Clinical Oncology, September 2018, Springer Science + Business Media

    Gloria Huang

  41. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma

    Article • Gynecologic Oncology, June 2018, Elsevier

    Gloria Huang

  42. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Gloria Huang

  43. In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

    Article • Molecular Cancer Therapeutics, April 2018, American Association for Cancer Research (AACR)

    Gloria Huang

  44. Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas

    Article • International Journal of Gynecological Cancer, March 2018, Elsevier

    Gloria Huang

  45. IGF2 is a prognostic biomarker in aggressive uterine cancer

    Article • Cancer Medicine, February 2018, Wiley

    Gloria Huang

  46. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression

    Article • Gynecologic Oncology, October 2017, Elsevier

    Gloria Huang

  47. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression

    Article • Gynecologic Oncology, July 2017, Elsevier

    Gloria Huang

  48. Genetics of Clear Cell Endometrial Cancer

    Article • Cancer, May 2017, Wiley

    Gloria Huang

  49. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma

    Article • Clinical Cancer Research, September 2016, American Association for Cancer Research (AACR)

    Gloria Huang

  50. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors

    Article • Cancer Causes & Control, April 2016, Springer Science + Business Media

    Gloria Huang

  51. Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor

    Article • Gynecologic Oncology Reports, January 2016, Elsevier

    Gloria Huang

  52. Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Article • Seminars in Cancer Biology, December 2015, Elsevier

    Professor Nicol Keith, Dr. H.P. Vasantha Rupasinghe, Colleen Curran, Dr Gunjan Guha, Tetsuro Sasada, Gloria Huang

  53. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds

    Article • Seminars in Cancer Biology, December 2015, Elsevier

    Professor Nicol Keith, Gloria Huang

  54. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors

    Article • Cancer Causes & Control, September 2015, Springer Science + Business Media

    Gloria Huang

  55. IGF2 signaling and regulation in cancer

    Article • Cytokine & Growth Factor Reviews, June 2015, Elsevier

    Gloria Huang

  56. The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics

    Article • Cancer Causes & Control, March 2015, Springer Science + Business Media

    Gloria Huang

  57. Transforming Growth Factor β1 and Extracellular Matrix Protease Expression in the Uterosacral Ligaments of Patients With and Without Pelvic Organ Prolapse

    Article • Female Pelvic Medicine & Reconstructive Surgery, January 2015, Wolters Kluwer Health

    Gloria Huang

  58. Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer

    Article • PLOS One, June 2014, PLOS

    Gloria Huang

  59. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma

    Article • Gynecologic Oncology, January 2012, Elsevier

    Gloria Huang

  60. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma

    Article • Gynecologic Oncology, January 2012, Elsevier

    Gloria Huang

  61. Clinical utility of chromogranin a and octreotide in large cell neuro endocrine carcinoma of the uterine corpus

    Article • Rare Tumors, November 2011, SAGE Publications

    Gloria Huang

  62. Downregulation of Filamin A Interacting Protein 1-Like is Associated with Promoter Methylation and Induces an Invasive Phenotype in Ovarian Cancer

    Article • Molecular Cancer Research, June 2011, American Association for Cancer Research (AACR)

    Dr Stephen M Hewitt, Gloria Huang

  63. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma

    Article • International Journal of Gynecological Cancer, April 2011, Wolters Kluwer Health

    Gloria Huang

  64. Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma

    Article • American Journal of Obstetrics and Gynecology, September 2010, Elsevier

    Gloria Huang

  65. Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer

    Article • Clinical Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Gloria Huang

  66. Extragenital adenosarcoma: A case report, review of the literature, and management discussion

    Article • Gynecologic Oncology, December 2009, Elsevier

    Gloria Huang

  67. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

    Article • Gynecologic Oncology, June 2009, Elsevier

    Gloria Huang

  68. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma

    Article • American Journal of Obstetrics and Gynecology, April 2009, Elsevier

    Gloria Huang

  69. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma

    Article • Gynecologic Oncology, December 2007, Elsevier

    Gloria Huang

  70. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors

    Article • American Journal of Obstetrics and Gynecology, March 2007, Elsevier

    Gloria Huang

  71. Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer

    Article • Cancer, January 2007, Wiley

    Gloria Huang

  72. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice

    Article • Clinical Cancer Research, January 2006, American Association for Cancer Research (AACR)

    Gloria Huang

  73. Consolidation therapy for ovarian cancer

    Article • The Women s Oncology Review, March 2005, Taylor & Francis

    Gloria Huang

  74. Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age

    Article • Gynecologic Oncology, October 2004, Elsevier

    Gloria Huang

  75. Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index

    Article • Gynecologic Oncology, April 2004, Elsevier

    Gloria Huang

  76. Total laparoscopic hysterectomy: body mass index and outcomes

    Article • Obstetrics and Gynecology, December 2003, Wolters Kluwer Health

    Gloria Huang

  77. Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar Adenocarcinoma

    Article • Gynecologic Oncology, December 2002, Elsevier

    Gloria Huang